Answer to Question 1
Correct Answer: 1,2
Rationale 1: All dihydropyridine calcium channel blockers are equivalent in effectiveness for treating hypertension.
Rationale 2: All dihydropyridine calcium channel blockers are equivalent in effectiveness for treating angina.
Rationale 3: Dihydropyridine calcium channel blockers are not utilized in the treatment of cerebrovascular disease.
Rationale 4: Dihydropyridine calcium channel blockers are not utilized in the treatment of deep vein thrombosis.
Rationale 5: Dihydropyridine calcium channel blockers are not utilized in the treatment of pulmonary embolism.
Global Rationale: All dihydropyridine calcium channel blockers are equivalent in effectiveness for treating hypertension and angina. Dihydropyridine calcium channel blockers are not utilized in the treatment of cerebrovascular disease, deep vein thrombosis, or pulmonary embolism.
Answer to Question 2
Correct Answer: 1,2,3
Rationale 1: Amlodipine (Norvasc) is a dihydropyridine calcium channel blocker.
Rationale 2: Felodipine (Plendil) is a dihydropyridine calcium channel blocker.
Rationale 3: Nicardipine (Cardene) is a dihydropyridine calcium channel blocker.
Rationale 4: Diltiazem (Cardizem) is a nondihydropyridine calcium channel blocker.
Rationale 5: Verapamil (Calan) is a nondihydropyridine calcium channel blocker.
Global Rationale: Amlodipine (Norvasc), felodipine (Plendil), and nicardipine (Cardene) are all dihydropyridine calcium channel blockers. Diltiazem (Cardizem) and verapamil (Calan) are both nondihydropyridine calcium channel blockers.